Literature DB >> 17499981

The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model.

Leonid Kagan1, Pavel Gershkovich, Avivit Mendelman, Sofia Amsili, Nathan Ezov, Amnon Hoffman.   

Abstract

The purpose of this study was to assess the contribution of lymphatics to the systemic bioavailability of macromolecules following SC administration in a rat model. The rat model included continuous lymph collection from the thoracic lymph duct and concurrent serial blood sampling from freely moving animals. A thoracic lymph duct-jugular vein shunt produced by an implanted connective cannula, and maintained during the recovery period, enabled superior rat survival and prevented lymphatic cannula occlusion. The SC absorption of three macromolecules (bovine insulin, bovine serum albumin, and recombinant human erythropoietin alpha) was assessed in comparison to the non-lymph cannulated control group. For all tested molecules, only minimal amounts (less than 3%) of the SC administered dose were detected in the collected lymph. In the rat model, following SC administration, the macromolecules were absorbed mainly through the blood capillaries with minimal contribution of the lymphatic system to systemic bioavailability. The relatively small elevation in the lymphatic concentration, which occurred in all molecules, may be attributed to the redistribution of the molecules from the blood to the interstitial fluid compartment. These findings are important since rodents are commonly used in preclinical evaluation of macromolecular drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499981     DOI: 10.1016/j.ejpb.2007.04.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  29 in total

1.  Administration of substances to laboratory animals: routes of administration and factors to consider.

Authors:  Patricia V Turner; Thea Brabb; Cynthia Pekow; Mary Ann Vasbinder
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

Review 2.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

Review 3.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

4.  A new stochastic approach to multi-compartment pharmacokinetic models: probability of traveling route and distribution of residence time in linear and nonlinear systems.

Authors:  Liang Zhao; Na Li; Harry Yang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-17       Impact factor: 2.745

Review 5.  Mechanistic determinants of biotherapeutics absorption following SC administration.

Authors:  Wolfgang F Richter; Suraj G Bhansali; Marilyn E Morris
Journal:  AAPS J       Date:  2012-05-23       Impact factor: 4.009

6.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

7.  In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Authors:  Vasco Filipe; Ivo Que; John F Carpenter; Clemens Löwik; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

8.  Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.

Authors:  Leonid Kagan; Jie Zhao; Donald E Mager
Journal:  Pharm Res       Date:  2014-05-23       Impact factor: 4.200

9.  Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats.

Authors:  Leonid Kagan; Michael R Turner; Sathy V Balu-Iyer; Donald E Mager
Journal:  Pharm Res       Date:  2011-09-02       Impact factor: 4.200

10.  PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

Authors:  Lisa M Kaminskas; David B Ascher; Victoria M McLeod; Marco J Herold; Caroline P Le; Erica K Sloan; Christopher J H Porter
Journal:  J Control Release       Date:  2013-03-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.